Advisors Dana Abramovitz

FILTER CONTENT

Research

By Simon EricksonPublished On: April 15, 2024
Dana’s April 2024 Conviction Rating Review
READ MORE
By Simon EricksonPublished On: March 21, 2024
Sell Vaxxinity
READ MORE
By Simon EricksonPublished On: March 15, 2024
Dana’s March 2024 Conviction Rating Review
READ MORE
By Simon EricksonPublished On: February 15, 2024
Dana’s February 2024 Conviction Rating Review
READ MORE
By Dana AbramovitzPublished On: January 22, 2024
Sell Selecta Biosciences (now Cartesian Therapeutics)
READ MORE
By Simon EricksonPublished On: January 9, 2024
Dana’s January 2024 Conviction Rating Review
READ MORE
By Dana AbramovitzPublished On: April 11, 2023
Despite the Drama, Illumina Celebrates 25 Years
READ MORE
By Dana AbramovitzPublished On: April 10, 2023
Sell Pear Therapeutics
READ MORE
By Dana AbramovitzPublished On: March 20, 2023
The Sweetness of Pear Therapeutics Sours in the Market
READ MORE
By Dana AbramovitzPublished On: February 10, 2023
Fortifying Its Foundation, Premier Continues on Its Path to Growth
READ MORE
By Dana AbramovitzPublished On: January 17, 2023
That’s a Wrap for JPM23, What did We Learn?
READ MORE
By Dana AbramovitzPublished On: January 10, 2023
JPM is Underway, Investor Updates and Deal-Making Galore!
READ MORE
By Dana AbramovitzPublished On: November 22, 2022
Sell BiomX
READ MORE
By Dana AbramovitzPublished On: November 22, 2022
Sell NeuBase Therapeutics
READ MORE
By Dana AbramovitzPublished On: November 9, 2022
With Tandem Diabetes Care Q3 Earnings, the Devil is in the Details
READ MORE
By Dana AbramovitzPublished On: October 30, 2022
Overcoming Some of the Complexities of Investing in Biotech
READ MORE